Quratis Inc. (KOSDAQ:348080)

Market Cap	70.17B
Revenue (ttm)	1.86B
Net Income (ttm)	-23.61B
Shares Out	73.86M
EPS (ttm)	-412.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	134,062
Average Volume	323,034
Open	953.00
Previous Close	953.00
Day's Range	930.00 - 977.00
52-Week Range	516.00 - 2,095.00
Beta	-0.51
RSI	40.86
Earnings Date	n/a

About Quratis

Quratis Inc. engages in developing vaccines in South Korea. It is involved in developing QTP101, a vaccine for tuberculosis; dendritic cell-based cell therapy for indications, including cancer, autoimmune, and infectious diseases; and peptide nucleic acid-based antimicrobial agents. The company also offers drugs contract development and manufacturing services. Quratis Inc. was founded in 2016 and is based in Seoul, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 348080

Financial Performance

In 2024, Quratis's revenue was 373.80 million, a decrease of -63.71% compared to the previous year's 1.03 billion. Losses were -26.27 billion, 54.6% more than in 2023.